JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:NVAX) with a Underweight and raises the price target from $8 to $9.
JP Morgan Maintains Underweight on Novavax, Raises Price Target to $9
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.